Navigation Links
Helix BioPharma announces Q1 2008 financial results
Date:12/17/2007

ompany's ongoing research and development programs.

At October 31, 2007, the Company had cash and cash equivalents totaling $9,578,000 (July 31, 2007 - $11,379,000), a decrease of $1,801,000 and working capital of $9,859,000 (July 31, 2007 - $11,468,000).

After taking into consideration the Company's anticipated revenue, planned research and development expenditures and assuming no unanticipated expenses, the Company expects that its working capital will be sufficient to finance operations through to September 2008. On the assumption that the private placement referred to below closes as planned, and then based on the same factors, the Company expects that it will have sufficient working capital to finance operations beyond the 2009 fiscal year.

Subsequent to the first quarter of fiscal 2008, the Company received subscriptions for the purchase, by way of private placement, of a total of 10,040,000 common shares at $1.68 per share, for gross proceeds totalling CDN$16,867,200. The Company anticipates closing the private placement before the end of December 2007.

The Company will continue to seek additional funding, primarily by way of equity offerings, to carry out its business plan and to minimize risks to its operations. The market, however, for equity financings for companies such as Helix is challenging, and there can be no assurance that additional funding by way of equity financing will be available. The failure of the Company to obtain additional funding on a timely basis may result in the Company reducing or delaying one or more of its planned research, development and marketing programs and reducing related personnel, any of which could impair the current and future value of the business. Any additional equity financing, if secured, may result in significant dilution to the existing shareholders at the time of such financing. The Company may also seek additional funding from other sources, including technology licensing, co-develop
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
11. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 The global market for biotechnology ... according to a new study by Grand View Research, ... for effective vaccines and drugs in an attempt to ... is expected to drive market demand over the next ... productivity via the use of genetically engineered seeds is ...
(Date:7/26/2014)... 2014 Canada Endoscopy Visualization Systems ... on the Canada Endoscopy Visualization Systems market. The ... volume (in units) and average prices (in US ... Systems, Mid-Range Endoscopy Visualization Systems and Low-End Endoscopy ... http://www.marketresearchreports.biz/analysis/213254 . , The report also provides company ...
(Date:7/25/2014)... July 25, 2014 Research and ... "Global Metabolomics Market 2014-2018" report to their ... Metabolomics or Metabonomics is the scientific ... become a new experimental technique that is being ... sciences. Metabolites are small molecules that are present ...
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
Breaking Biology Technology:Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6
... May 11 Amicus Therapeutics (Nasdaq: ... Matthew R. Patterson, will be presenting at the upcoming Bank ... Mr. Patterson,s presentation is scheduled to begin on Wednesday, ... live webcast of the presentation by logging on to the ...
... NEW YORK, May 11 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, Inc. ... to,improving health through the development, manufacture and commercialization of,a ... products in China,today announced financial results for the first ... Financial Results , Revenue ...
... May 9 Oxford Biomedica,s,second attempt to dismiss Bavarian ... Instead of denying infringement, Oxford Biomedica,made yet another attempt ... TroVax(R) was still evaluated in clinical trials. The court ... based on the,substance of the patents. , ...
Cached Biology Technology:American Oriental Bioengineering Reports First Quarter 2009 Financial Results 2American Oriental Bioengineering Reports First Quarter 2009 Financial Results 3American Oriental Bioengineering Reports First Quarter 2009 Financial Results 4American Oriental Bioengineering Reports First Quarter 2009 Financial Results 5American Oriental Bioengineering Reports First Quarter 2009 Financial Results 6American Oriental Bioengineering Reports First Quarter 2009 Financial Results 7The Court Supports Bavarian Nordic's Decision to Start Patent Infringement Case Against Oxford BioMedica 2
(Date:7/27/2014)... revealed that nicotine and cotinine, a metabolite of nicotine, ... carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK ... ultimately ends up in the tobacco smoke. Once inhaled, ... it is activated by a variety of enzymes called ... that nicotine can partially interfere with the activation of ...
(Date:7/27/2014)... like bacteria and fungi can evade treatment by acquiring ... drugs. These permanent mutations were once thought to be ... a new study has shown that microorganisms can use ... epimutations -- to gain the benefits of drug resistance ... discovered in a fungus called Mucor circinelloides, it is ...
(Date:7/27/2014)... from over 18,000 patients, scientists have identified more ... Parkinson,s disease, including six that had not been ... Genetics , was partially funded by the National ... working in NIH laboratories. , "Unraveling the genetic ... multiple mechanisms involved in this complex disease, and ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3NIH scientists find 6 new genetic risk factors for Parkinson's 2
... Just as scientists finished sequencing the human genome, they ... DNA produces proteins to sustain life, they found microRNA. ... channel in biology, allowing scientists to more closely examine ... tick. "This is a pivotal mechanism for solving ...
... Ore Oregon Health & Science University researchers, along ... uncovering new information about the mind by studying the ... this research will one day provide new tools for ... treatments. The researchers, latest findings are published in the ...
... Universit de Montreal (UdeM) and the Montreal Neurological Institute ... support nerve cell (neuron) survival also play an active ... the eye. The findings, published this week in The ... streamlined therapies for a variety of acute and chronic ...
Cached Biology News:Meet DNA's personal assistants 2OHSU researchers study the idling brain 2Cell's split personality is a major discovery into neurological diseases 2
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
... Cloning is the most ... cloning PCR products. TOPO ... Blunt TOPO vectors are ... with topoisomerase I. This ...
Applications: ISH...
... ZMD.420. Immunogen: Recombinant human ... Specific for the ~44 kDa ... Human (positive control: IFN-Gamma-stimmulated Human ... sequence homology reactivity with mouse ...
Biology Products: